Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Non-Current Assets (2019 - 2026)

Pliant Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $27.7 million for Q1 2026.

  • Quarterly Non-Current Assets fell 17.61% to $27.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $119.8 million through Mar 2026, down 14.45% year-over-year, with the annual reading at $28.8 million for FY2025, 17.02% down from the prior year.
  • Non-Current Assets was $27.7 million for Q1 2026 at Pliant Therapeutics, down from $28.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $36.2 million in Q2 2024 and troughed at $6.1 million in Q3 2023.
  • The 5-year median for Non-Current Assets is $27.7 million (2026), against an average of $21.6 million.
  • Year-over-year, Non-Current Assets crashed 45.35% in 2023 and then soared 481.4% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $10.3 million in 2022, then plummeted by 35.43% to $6.7 million in 2023, then soared by 421.42% to $34.7 million in 2024, then fell by 17.02% to $28.8 million in 2025, then fell by 3.87% to $27.7 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Non-Current Assets are $27.7 million (Q1 2026), $28.8 million (Q4 2025), and $31.0 million (Q3 2025).